If you're an investor in the Australian Stock Market, you may be curious about technology's growing impact on traditional industries. Artificial intelligence (AI) is revolutionizing how businesses operate and how investors assess potential returns. My learning curve in the space of AI is now my favourite topic of conversation. In the space of a month, my curiosity about this business has evolved from a casual conversation to one that is generating a passion for the business.

SINGAPORE, 18 June 2025 – The Marina Bay Sands has transformed into the epicentre of artificial intelligence innovation as SuperAI 2025 goes live. With over 7,000 attendees, 1,000+ AI companies from 100+ countries, and a sold-out floor of 150+ exhibitors, this year’s edition is not just an event – it’s a signal. A signal that Asia’s role in shaping the AI future is not coming – it’s here.

As someone who’s followed Miramar Resources (ASX: M2R) since its IPO, I’ve always been intrigued by the Whaleshark Project. Located about 40km east of Onslow in Western Australia’s Ashburton region, this project has been on my radar due to its promising geology. But the recent announcement has taken my interest to a whole new level.

Investing in mineral exploration stocks on the ASX can offer exciting opportunities, but it also carries unique challenges. With over 30 years of experience as a geologist in the industry, I have witnessed both the highs and lows of the mineral resource market. I have seen proejcts go from a Urnaium project to being a Phosphate project in 6 months and Nickel to Gold or vice versa, in a simialr time frame. Knowing the complexities in this sector is vital for making informed i

In the crowded corridors of medtech innovation, it's easy to get swept up in buzzwords—AI-powered, minimally invasive, precision diagnostics. But every now and then, a company emerges with more than just jargon—it comes armed with transformative tech, a clear path to market, and the traction to back it up.

When I reviewed LinQ Minerals Limited’s IPO Replacement Prospectus (27 May 2025) and accompanying investor presentation, it was clear this is not your standard greenfields hopeful. LinQ offers something much more compelling: a genuine brownfields gold-copper project with real tonnage, credible grade, deep geological understanding, and—importantly—a team that’s been here before.

When it comes to spotting undervalued potential in biotech, I often look for companies that are not only developing novel technologies but also demonstrating clear paths to commercialisation. This month, three small-cap names on the ASX have really caught my attention: Memphasys Limited (ASX: MEM), Control Bionics (ASX: CBL), and dorsaVi Ltd (ASX: DVL). Each is on a very different mission, but all three are making measurable progress—and investors are starting to notice.

When a project keeps delivering—consistently, scalably, and with geological integrity—you start paying closer attention. The latest update from Peak Minerals Ltd (ASX: PUA) is not just another batch of numbers. It’s a lesson in how overlooked jurisdictions, sound geoscience, and strategic persistence can converge to reveal something much bigger.

At Samso, we often talk about “first movers” and “market makers” in the mining and tech sectors. But when it comes to mental health care, particularly treatment-resistant conditions like Post-traumatic stress disorder (PTSD), the stakes aren’t just commercial. They’re deeply personal.

Let’s be honest: endometriosis has long been one of the most underdiagnosed and misunderstood medical conditions in women's health. A silent disruptor, it causes pain, fertility issues, and decades-long suffering, often without a name. Until now, the only path to a diagnosis was invasive laparoscopic surgery, usually after seven years of misdiagnosis. That’s not a system built for healing. But what if we could change that narrative with a simple blood test?